Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Veloxis Pharmaceuticals A/S    VELO   DK0060048148

 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Omx Copenhagen
12/06/2017 12/07/2017 12/08/2017 12/11/2017 12/12/2017 Date
0.79(c) 0.78(c) 0.785(c) 0.775(c) 0.8 Last
519 128 1 161 330 1 464 527 1 481 766 852 338 Volume
-1.86% -1.27% +0.64% -1.27% +3.23% Change
More quotes
Financials ( DKK)
Sales 2017 184 M
EBIT 2017 -50,7 M
Net income 2017 -12,7 M
Debt 2017 88,8 M
Yield 2017 -
Sales 2018 184 M
EBIT 2018 -57,1 M
Net income 2018 38,1 M
Debt 2018 146 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 7,70x
EV / Sales2018 8,01x
Capitalization 1 327 M
More Financials
Company
Veloxis Pharmaceuticals A/S is a commercial-stage specialty pharmaceutical company, which engages in the development and commercialization of medicine for the prevention of organ rejection in kidney transplant patients.The company is focused on the direct commercialization of Envarsus XR in the US,... 
More about the company
Latest news on VELOXIS PHARMACEUTICALS A/
12/04 VELOXIS PHARMACEUTICALS A/S : Increases Share Capital in Connection with Exercis..
12/01 VELOXIS PHARMACEUTICALS A/S : Increases Share Capital in Connection with Exercis..
11/14 VELOXIS PHARMACEUTICALS A/S : Announces Financial Results for the First Nine Mon..
11/09VELOXIS PHARMACEUTICALS A/S : quaterly earnings release
11/03 VELOXIS PHARMACEUTICALS A/S : AS Grants Warrants Under Existing Warrant Program
10/31 VELOXIS PHARMACEUTICALS A/S : Grants Warrants Under Existing Warrant Program
10/12 VELOXIS PHARMACEUTICALS A/S : Patent Issued for Regimen for Supressing Organ Rej..
09/28 VELOXIS PHARMACEUTICALS A/S : Patent Issued for Solid Dispersions Comprising Tac..
09/25 VELOXIS PHARMACEUTICALS A/S : Alastair McEwan Steps Down as Chief Operating Offi..
09/21 VELOXIS PHARMACEUTICALS A/S : Inc., Appoints Ulf Meier-Kriesche, MD, as Chief Sc..
More news
Sector news : Biotechnology & Medical Research - NEC
12:46p Sanofi investors hungry for drug progress and deal news
10:43a M&A dominates Europe share trading as oil leads gains
12/09 Tax-loss selling to pressure 2017's losers in December
11/30 GENMAB : and J&J 'love' partnership as some ponder takeover
11/27 MERCK AND : As Brexit looms, UK pitches new industry plan, wins support from Mer..
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
2016 Veloxis Pharmaceuticals reports 1H16 results
2015 Veloxis Pharma's once-daily Envarsus an Orphan Drug for prevention of organ r..
2015 PREMARKET BIOTECH DIGEST : Pfizer In China, Anavex Alzheimer's Focus
2015 FDA clears Veloxis Pharma's extended-release Envarus for the prevention of re..
Chart VELOXIS PHARMACEUTICALS A/
Duration : Period :
Veloxis Pharmaceuticals A/ Technical Analysis Chart | VELO | DK0060048148 | 4-Traders
Technical analysis trends VELOXIS PHARMACEUTICALS A/
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus
Number of Analysts 2
Average target price 0,86  DKK
Spread / Average Target 11%
EPS Revisions
Managers
NameTitle
Craig A. Collard President & Chief Executive Officer
Michael Thomas Heffernan Chairman
Ulf Meier-Kriesche Chief Scientific Officer
Anders Götzsche Independent Director
Mette Kirstine Agger Deputy Chairman
Sector and Competitors
1st jan.Capitalization (M$)
VELOXIS PHARMACEUTICALS A/S-27.31%210
CELLTRION, INC.--.--%23 085
IQVIA HOLDINGS INC32.70%21 148
INCYTE CORPORATION-5.43%20 523
LONZA GROUP57.44%19 299
ALNYLAM PHARMACEUTICALS, INC.243.83%12 606